天津医药 ›› 2016, Vol. 44 ›› Issue (12): 1496-1499.doi: 10.11958/20160511

• 临床研究 • 上一篇    下一篇

甲状腺乳头状癌中CA19-9、 CA15-3 和 CA125的表达及意义

侯卫东1 , 王俊宏1△, 张志宇1 , 李进1 , 刘艳晓1 , 丁红霞1 , 禹远远1 , 田勇1 , 刘艳峰2   

  1. 1 河南省平顶山市第一人民医院内分泌代谢科 (邮编 467000); 2 中国人民解放军 152医院病理科
  • 收稿日期:2016-06-06 修回日期:2016-09-26 出版日期:2016-12-15 发布日期:2017-01-26
  • 通讯作者: 王俊宏 △通讯作者 E-mail: hou_dm@126.com E-mail:hou_dm@126.com
  • 作者简介:侯卫东 (1981), 男, 硕士, 主治医师, 主要从事内分泌代谢疾病的基础与临床研究

Expressions of CA19-9, CA15-3 and CA125 and their significance in papillary thyroid carcinoma

HOU Weidong , WANG Junhong , ZHANG Zhiyu , LI Jin , LIU Yanxiao , DING Hongxia , YU Yuanyuan , TIAN Yong , LIU Yanfeng2   

  1. 1 Division of Endocrinology, Pingdingshan Municipal First People’ s Hospital, Pingdingshan 467000, China; 2 Department of Pathology, People’ s Liberation Army 152 Hospital
  • Received:2016-06-06 Revised:2016-09-26 Published:2016-12-15 Online:2017-01-26
  • Contact: WANG Junhong △Corresponding Author E-mail: hou_dm@126.com E-mail:hou_dm@126.com

摘要: 摘要: 目的 探讨糖类抗原 19-9 (CA19-9)、 糖类抗原 15-3 (CA15-3) 和糖类抗原 125 (CA125) 在甲状腺乳头状癌 (PTC) 中的表达及临床意义。方法 采用免疫组化 MaxVision 两步法检测 80 例 PTC 和 80 例甲状腺良性病变(BTL, 包括 34 例结节性甲状腺肿、 26 例桥本甲状腺炎和 20 例滤泡性腺瘤) 患者中 CA19-9、 CA15-3 和 CA125 的表达状况, 分析其表达与 PTC 患者临床病理特征的关系。结果 80 例 PTC 中 CA19-9、 CA15-3、 CA125 阳性表达率分别为 85.0%、 100.0%、 43.8%, 与 BTL 相比, 差异具有统计学意义 (P<0.01)。CA19-9、 CA15-3、 CA125 的表达与患者年龄、 性别、 瘤结节数目、 直径、 淋巴结转移及 TNM 分期无关 (P>0.05)。CA19-9、 CA15-3、 CA125 诊断 PTC 的灵敏度分别为 85.0%、 100.0%、 43.8%, 特异度分别为 91.3%、 36.3%、 91.3%。结论 CA19-9、 CA153、 CA125 的表达有助于 PTC 和 BTL 的鉴别诊断。

关键词: 甲状腺肿瘤, 癌, 乳头状, 免疫组织化学, 诊断, 鉴别, 敏感性与特异性, CA-19-9 抗原, CA-15-3 抗原, CA-125 抗原

Abstract: Abstract: Objective To investigate the expressions of carbohydrate antigen 19-9(CA19-9), carbohydrate antigen 15- 3(CA15- 3) and carbohydrate antigen 125(CA125) and their clinical significance in papillary thyroid carcinoma (PTC). Methods The expressions of CA19-9, CA15-3 and CA125 were detected by immunohistochemical MaxVision method in 80 cases of PTC and 80 cases of benign thyroid lesions (BTL), including 34 cases of nodular goiter, 26 cases of Hashimoto's thyroiditis and 20 cases of follicular adenoma. The relationship between expressions of CA19-9, CA15-3 and CA125 and the clinical pathological characteristics were analyzed. Results The expression rates of CA19-9, CA15-3 and CA125 in 80 cases of PTC were 85%, 100% and 43.8% respectively, compared with BTL, the difference was statistically significant (P < 0.01). There was no significant correlation between expressions of CA19- 9, CA15- 3 and CA125 and age, gender, number and diameter of tumor nodules, lymph node metastasis, and TNM staging (P > 0.05). The sensitivity of CA19-9, CA15- 3 and CA125 in the differential diagnosis of PTC and BTL were 85%, 100% and 43.8% respectively, and the specificity were 91.3%, 36.3% and 91.3%, respectively. Conclusion The expressions of CA19-9, CA153 and CA125 are helpful for the differential diagnosis of PTC and BTL.

Key words:  thyroid neoplasms, carcinoma, papillary, immunohistochemistry, diagnosis, differential, sensitivity and specificity, CA-19-9 antigen, CA-15-3 antigen, CA-125 antigen